Schlieren, Switzerland

Anke Judith Harsman

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Limmatech Biologics Ag. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Anke Judith Harsman: Innovator in Glycoengineering

Introduction

Anke Judith Harsman is a notable inventor based in Schlieren, Switzerland. She has made significant contributions to the field of glycoengineering, particularly through her innovative approaches to genetic engineering.

Latest Patents

Anke holds a patent for her work titled "Glycoengineering using cells." This patent relates to cells that have been genetically engineered to reduce or eliminate the formation of an O-linked GlcNAc on a polypeptide. The process involves catalyzing the formation of O-linked GlcNAc in the cell prior to genetic engineering by at least one N-acetylglucosamine (GlcNAc)-transferase. Additionally, her patent provides methods for producing polypeptides using the described cells and outlines the polypeptides produced by these methods. Anke has 1 patent to her name.

Career Highlights

Anke Judith Harsman is associated with Limmatech Biologics AG, where she continues to advance her research in glycoengineering. Her work has implications for various applications in biotechnology and pharmaceuticals.

Collaborations

Anke collaborates with talented individuals in her field, including Amirreza Faridmoayer and Manuela Mally. These collaborations enhance the innovative potential of her research and contribute to the advancement of glycoengineering.

Conclusion

Anke Judith Harsman is a pioneering inventor whose work in glycoengineering is shaping the future of biotechnology. Her contributions are significant and continue to influence the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…